A composition for relieving atopic dermatitis, its preparation method and application.
By using a specific ratio of hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid, the skin irritation and safety deficiencies of existing atopic dermatitis products are resolved, achieving the effects of skin barrier repair and microecological stability, and significantly alleviating atopic dermatitis symptoms.
Patent Information
- Application Number
- CN202611472154.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-21
- Publication Date
- 2026-11-10
AI Technical Summary
Existing topical care products for relieving atopic dermatitis have issues such as skin irritation, hormone dependence, and insufficient safety, and their effects on skin barrier repair and microecological maintenance are limited.
A combination of hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid is formulated in a specific ratio, and skin barrier repair agents and anti-inflammatory agents such as ceramide NP, ceramide EOP, and bisabolol are added to prepare topical dosage forms such as ointments, creams, and sprays for the treatment of skin inflammation.
This composition significantly inhibits Th2 immune responses, reduces skin inflammation, promotes skin barrier repair, increases skin hydration, and improves dryness, sensitivity, and itching associated with atopic dermatitis. It also demonstrates good safety and long-term suitability.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a composition for relieving atopic dermatitis, its preparation method, and its application. Background Technology
[0002] Atopic dermatitis (AD), also known as atopic eczema, is a common chronic, relapsing inflammatory skin condition, primarily characterized by redness, dryness, itching, and lichenification of the skin. Its development is closely related to impaired skin barrier function, immune imbalance, and skin microecological dysbiosis. After the skin barrier is damaged, keratinocytes can release various alarm factors and chemokines, promoting the activation of type II innate lymphocytes and Th2 cells, and inducing the production of type II cytokines such as IL-4, IL-13, and IL-31. These factors can further inhibit the expression of tight junction proteins and other skin barrier-related proteins, and promote the infiltration of inflammatory cells. Furthermore, atopic dermatitis is often accompanied by abnormal proliferation of Staphylococcus aureus and an imbalance in the gut microbiota, while IL-4 and IL-13 can also inhibit the production of antimicrobial peptides, further weakening the skin's ability to resist external microorganisms.
[0003] Currently, topical care for atopic dermatitis mainly includes moisturizers, corticosteroids, calcineurin inhibitors, and phosphodiesterase 4 inhibitors. However, long-term use of some existing products may lead to skin irritation, hormone dependence, or insufficient safety profiles, and their overall effectiveness in repairing the skin barrier, maintaining the skin's microecology, and reducing recurrence is limited. Summary of the Invention
[0004] In view of this, the purpose of the present invention is to provide a pharmaceutical composition for relieving atopic dermatitis, which has the effects of anti-skin allergy and inflammation and repairing the skin barrier.
[0005] This invention provides a composition comprising hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid; The mass ratio of the hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid is 0.8~1.0:1.3~1.7:2.8~3.2:4.8~5.2.
[0006] Preferably, the mass ratio of the hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid is 1:1.5:3:5.
[0007] Preferably, the composition further includes a skin barrier repair agent and / or an anti-inflammatory agent; When the composition includes a skin barrier repair agent, the skin barrier repair agent includes one or more of ceramide NP, ceramide EOP, and cholesterol; The mass ratio of hydroxyphenylpropionamide benzoic acid, ceramide NP, ceramide EOP and cholesterol is 0.8~1.0:0.06~0.068:0.028~0.032:0.013~0.017; When the composition includes a skin barrier repair agent, the anti-inflammatory agent is bisabolol; The mass ratio of hydroxyphenylpropionamide benzoic acid to bisabolol is 0.8~1.0:1.8~2.2.
[0008] The present invention provides the use of the composition in the preparation of pharmaceuticals for the prevention and / or treatment of skin inflammation or in the preparation of cosmetics for the relief of skin inflammation.
[0009] Preferably, the skin inflammation includes atopic dermatitis.
[0010] Preferably, the atopic dermatitis includes at least one of the following symptoms: skin allergy, skin inflammation, and skin barrier damage.
[0011] Preferably, the dosage form of the product includes at least one of the following external dosage forms: ointment, cream, and spray.
[0012] Preferably, the cosmetic product includes at least one of the following types: lotion, cream, and lotion.
[0013] Preferably, the concentration of dipotassium glycyrrhizate in the drug or cosmetic is 0.28-0.32%.
[0014] This invention provides a product for relieving atopic dermatitis, comprising the composition and pharmaceutically or cosmetically acceptable excipients.
[0015] This invention provides a composition comprising hydroxyphenylpropionamide benzoic acid, asiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid in a strict mass ratio of 0.8-1.0:1.3-1.7:2.8-3.2:4.8-5.2. The four active ingredients exhibit multi-target synergistic regulation. Hydroxyphenylpropionamide benzoic acid has soothing, antipruritic, and skin barrier repair-promoting effects, promoting keratinocyte proliferation and migration and increasing tight junction protein expression; asiaticoside has antioxidant, soothing, and skin repair-promoting effects; dipotassium glycyrrhizate has anti-inflammatory, anti-allergic, and skin discomfort-relieving effects; and tetrahydromethylpyrimidine carboxylic acid has moisturizing, cell membrane-stabilizing, skin barrier-enhancing, and external irritant-reducing effects. The active ingredients work synergistically to soothe inflammatory responses, reduce itching and redness, increase skin hydration, promote barrier-related protein expression, and maintain skin microecological stability, thereby improving dryness, sensitivity, itching, and barrier damage associated with atopic dermatitis. Experiments showed that the composition possesses anti-skin inflammation, inhibits the expression of immune response-related factors, and suppresses immune cell-mediated Th2 pro-polarization signals. Simultaneously, animal experiments demonstrated that, compared to the control group, the composition significantly improved calcipotriol-induced atopic dermatitis in mice with ear thickening, alleviated ear edema, erythema, and desquamation, reduced transcutaneous water loss from the auricle in model mice, inhibited ear inflammation, and suppressed CD4+. + The composition also improves the infiltration of T cells into skin tissue. Furthermore, it repairs skin barrier damage and increases the expression of skin keratinocyte barrier-related factors and ear barrier-related proteins. In addition, in vivo safety evaluation results showed that the blood routine indicators of mice after administration of the composition were all within the safe range, and biochemical indicators showed no significant changes compared with the blank control mice. Therefore, this invention develops a non-hormonal drug composition with good safety, suitable for long-term use, and possessing soothing, moisturizing, barrier repair, and microecological regulation effects, providing a new treatment approach for skin inflammation, especially atopic dermatitis. Attached Figure Description
[0016] Figure 1 The effect of drug components on keratinocyte viability; Figure 2 The effect of the drug composition on the expression of Th2-type immune response-related factors; Note: p <0.05, p <0.01; Figure 3 For the drug composition to target initial CD4 + Inhibitory effect of T cell polarization towards Th2 cells; p <0.05, p <0.01, p <0.001, p <0.0001; Figure 4 This describes the inhibitory effect of the pharmaceutical composition on TSLP-induced maturation of bone marrow-derived dendritic cells; Note: p <0.0001; Figure 5 The effect of the drug composition on thickening of the ear epidermis in mice; Figure 6 The effect of the drug composition on ear edema, erythema, and desquamation in mice; Note: p <0.01, p <0.001, p <0.0001; Figure 7 Effect of the drug composition on percutaneous water loss of mouse auricle; Note: p <0.0001; Figure 8 This indicates the inhibitory effect of the pharmaceutical composition on M2 macrophage polarization; Note: p <0.01; Figure 9 For the drug composition on CD4 + Inhibition of T cell infiltration into skin tissue; Note: p <0.01; Figure 10 This describes the effect of the pharmaceutical composition on improving the expression levels of skin barrier-related genes in AD-like keratinocytes; Note: p <0.01, p <0.0001; Figure 11 This describes the effect of the pharmaceutical composition on improving the expression levels of skin barrier-related proteins; Note: p <0.05, p <0.01, p <0.0001; Figure 12 This study evaluated the safety of the pharmaceutical composition in mouse serum creatinine (CREA), urea (BUN), uric acid (UA), alanine aminotransferase (ALT), and aspartate aminotransferase (AST); Note: ns indicates no significant difference between the two groups. p Greater than 0.05. Detailed Implementation
[0017] The present invention provides a composition comprising hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate and tetrahydromethylpyrimidine carboxylic acid.
[0018] In this invention, the mass ratio of hydroxyphenylpropionamide benzoic acid (denoted as A), hydroxyasiaticoside (denoted as C), dipotassium glycyrrhizate (denoted as G) and tetrahydromethylpyrimidine carboxylic acid (denoted as E) is 0.8~1.2:1.3~1.7:2.8~3.2:4.8~5.2; or it can be 1:1.5:3:5.
[0019] In this invention, the asiaticoside can be replaced by a composition C1 of asiaticoside and asiaticoside, or a composition C2 of asiaticoside, asiaticus extract, and asiaticoside. In composition C1, the mass ratio of asiaticoside to asiaticoside is preferably 48-49:1-2, and can also be 97:3. In composition C2, the mass ratio of asiaticoside, asiaticus extract, and asiaticoside is preferably 90-94:4-6:2-4, and can also be 92:5:3. More than 90% of the components in the asiaticus extract are asiaticoside, and can be up to 92%. In this embodiment, the asiaticus extract was purchased from Guilin Rhine Biotechnology Co., Ltd., batch number: F260313.
[0020] In one embodiment of the present invention, the composition C1, based on 100% by mass, contains 90% to 94% asiaticoside, which can be 92% by mass. The Centella asiatica extract contains 4% to 6% by mass, which can be 5% by mass. The asiaticoside content is 2.5% to 3.5% by mass, which can be 3% by mass. In another embodiment of the present invention, the composition C2, based on 100% by mass, contains 92% asiaticoside and 5% Centella asiatica extract by mass.
[0021] In this invention, the compound of hydroxyphenylpropionamide benzoic acid, asiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid exhibits a synergistic effect. In one embodiment of this invention, three different compositions (CAE, AGE, CGE, and CAG) formed by combining three of the above four components showed poorer anti-inflammatory activity compared to the composition (CAGE) formed by the four components protected in this invention. For example, to evaluate the efficacy of the compositions and detect the pathogenesis of Th2-dominated inflammatory skin diseases, the expression levels of Th2-type immune response-related factors in HaCat cells were used to reflect the differences in the effects of the compositions. The results showed that the three different compositions formed by combining the three components exhibited different effects on the relative gene expression levels of IL-33, IL-31, TSLP, and CCL17 factors. Compared with the model group, CAE, AGE, and CAG had a certain degree of inhibitory effect on the expression of IL-33, IL-31, TSLP, and CCL17 factors, but the degree of inhibition was not as great as that of the composition (CAGE). The CGE composition only showed some inhibitory effect on the expression of TSLP factor, while it not only had no inhibitory effect on the expression of IL-33, IL-31, and CCL17 factors, but also showed higher levels than the model group, exhibiting the opposite pharmacological effect. In contrast, the composition group of this invention (CAGE) significantly reduced the expression of IL-33, IL-31, TSLP, and CCL17 factors compared to the model group, and the degree of reduction was superior to that of the three-component composition. This indicates that the composition of the active pharmaceutical ingredient directly affects the therapeutic effect on skin inflammation. This invention has screened and obtained a drug with good inhibitory effect on immune response, achieving the therapeutic effect of suppressing skin allergies.
[0022] In another embodiment of the present invention, the effect of the proportions of the components on efficacy was assessed by adjusting the mass ratios of hydroxyphenylpropionamide benzoic acid, asiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid. A control composition was prepared at a mass ratio of 1:1:1:1, while a composition (CAGE) was prepared at a mass ratio of 1:1.5:3:5. The difference in efficacy between the two compositions was reflected by the expression levels of Th2-type immune response-related factors in HaCat cells. The results showed that, compared with the model group, the control composition did not significantly reduce IL-33, IL-31, TSLP, and CCL17, while the composition (CAGE) of the present invention significantly reduced IL-33, IL-31, TSLP, and CCL17. This indicates that the mass ratio range of the composition is also an important factor affecting the efficacy of the immunosuppressive drug. Therefore, the composition formed by the above four components in a specific mass ratio, protected by the present invention, has good efficacy in inhibiting Th2-type immune responses.
[0023] In this invention, the composition preferably further comprises a skin barrier repair agent and / or an anti-inflammatory agent. The skin barrier repair agent preferably comprises one or more of ceramide NP, ceramide EOP, and cholesterol. The soothing anti-inflammatory agent is preferably bisabolol. The mass ratio of hydroxyphenylpropionamide benzoic acid to bisabolol is 0.8~1.0:1.8~2.2, which can be 1:2. The mass ratio of hydroxyphenylpropionamide benzoic acid to ceramide NP, ceramide EOP, and cholesterol is 0.8~1.0:0.06~0.068:0.028~0.032:0.013~0.017, which can be 1.0:063:0.03:0.015.
[0024] The present invention does not impose any particular limitation on the preparation method of the composition; any composition preparation method well known in the art can be used, such as the traditional oil-in-water (O / W) emulsification method.
[0025] The present invention provides the use of the composition in the preparation of pharmaceuticals for the prevention and / or treatment of skin inflammation or in the preparation of cosmetics for the relief of skin inflammation.
[0026] In this invention, the skin inflammation preferably includes atopic dermatitis. Atopic dermatitis includes at least one of the following symptoms: skin allergy, skin inflammation, and skin barrier damage.
[0027] In this invention, patients with atopic dermatitis often experience skin allergies. Th2 immune responses (characteristically secreting cytokines such as IL-4, IL-5, and IL-13) are a core driving factor in atopic dermatitis. Therefore, the upregulation of Th2 immune response-related factors in skin cells reflects the efficacy of the composition in treating skin allergies. The Th2 immune response-related factors include at least one of the following: IL-31, TSLP, CCL17, and IL-33. In one embodiment of this invention, an AD-like HaCat cell model was used as the experimental subject to evaluate the efficacy of the composition. The results showed that, compared with the blank control group, all Th2 immune response-related factors in the model group were significantly upregulated. The composition (CAGE) group significantly reduced the expression of these factors, achieving a statistically significant difference.
[0028] In this invention, skin inflammation is a typical symptom of atopic dermatitis. When skin inflammation occurs, specific immune cells are activated to participate in the inflammatory response, such as the maturation induction of dendritic cells (DCs) and the initial CD4+ activation. + The degree of T cell polarization towards Th2 cells. In one embodiment of the present invention, the degree of TSLP-induced maturation of bone marrow-derived dendritic cells (BMDCs) was used to reflect the efficacy of the composition in inhibiting skin inflammation. Results showed that TSLP stimulation significantly upregulated the expression of CD80, CD86, and OX40L in BMDCs, indicating successful induction of a mature DC phenotype with Th2-promoting polarization capabilities. After treatment with the drug composition, the expression of CD80 and CD86 decreased in a concentration-dependent manner; simultaneously, low-dose drug composition downregulated OX40L expression, indicating that the drug composition could attenuate TSLP-induced DC maturation and inhibit OX40L-mediated Th2-promoting polarization signaling within a certain concentration range. In another embodiment of the present invention, the effect of the composition on Na+ was also measured. The study investigated the effect of Na+ on Th2 polarization in CD4+ T cells, and the results showed that Na+ extracted and sorted from the spleen of Balb / c mice... With increasing concentration of the drug composition, CD4 T cells were induced to adopt a Th2 phenotype. + T cells (CD4) + IL-4 + The proportion of Na+ decreased significantly. This result confirms that the drug composition has a significant effect on Na+. It inhibits the Th2 polarization of CD4+ T cells.
[0029] In another embodiment of the invention, a calcipotriol-induced mouse auricular swelling and inflammation model was used to verify the efficacy of the composition and evaluate its anti-inflammatory and anti-allergic effects. The product containing the composition not only significantly reduced auricular thickening, erythema, and desquamation caused by calcipotriol, but also, as shown by H&E staining results, significantly improved skin lesions, including epidermal hyperplasia, acanthosis, hyperkeratosis with parakeratosis, significant intercellular edema (sponge formation), and elongation of the ridges.
[0030] In this invention, skin barrier damage is a significant symptom of atopic dermatitis. Skin barrier function depends on the intricate structure of the stratum corneum; disruption of this structure weakens barrier function. Furthermore, Th2 cytokines attacking the skin barrier also affect its structural integrity and function. For example, existing technologies have demonstrated that cytokines such as IL-4, IL-13, and IL-22 can directly damage the skin barrier. Based on this, the development of atopic dermatitis forms a self-perpetuating cycle of "barrier damage → inflammation initiation → further barrier damage." Simultaneously, skin barrier damage can recruit dermal γδT cells through IL-1 signaling, further amplifying the inflammatory response.
[0031] In one embodiment of the present invention, using an AD-like HaCat cell model as the subject, the efficacy of the product containing the composition in repairing skin barrier damage was investigated. Results showed that the product containing the composition could restore the expression levels of barrier-related factor mRNAs (TJP3, FLG) in AD-like skin keratinocytes, and also restore the expression levels of calcipotriol-induced barrier-related proteins (PPARγ, Occludin, Claudin1) in mouse ears. This demonstrates that the composition or the product containing the composition can improve barrier tightness, correct abnormal compensatory states, and promote barrier repair.
[0032] In this invention, the dosage form of the medicine preferably includes at least one of the following external dosage forms: ointment, cream, and spray. The type of cosmetic includes at least one of the following: lotion, cream, and lotion. In the medicine or cosmetic, the concentration of dipotassium glycyrrhizate is 0.28-0.32%, and can be 0.3%.
[0033] This invention provides a product for relieving atopic dermatitis, comprising the composition and pharmaceutically or cosmetically acceptable excipients.
[0034] In this invention, the pharmaceutically or cosmetically acceptable excipients preferably include at least one of the following: solvents, humectants, emollients, co-emulsifiers, emulsifiers, preservatives, pH adjusters, and plasticizers. The solvents and humectants preferably include at least one of the following: water, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, and glycerin. The humectants may also be glyceryl glucoside, panthenol, or collagen. The emollients preferably include polydimethylsiloxane, caprylic / capric triglyceride, and C13-14 isoparaffins. The co-emulsifier is preferably cetearyl alcohol. The emulsifier is preferably cetearyl oleate, sorbitan oleate, polyacrylamide, lauryl ether-7, polyglycerol-10 stearate, polyglycerol-6 behenate, glyceryl stearates, and sodium cetearyl sulfate. The preservative synergist is preferably p-hydroxyacetophenone, sodium levulinate, or potassium sorbate. The pH adjuster may be citric acid. The plasticizer may be triethyl citrate.
[0035] The following detailed description, in conjunction with embodiments, illustrates a composition for relieving atopic dermatitis provided by the present invention, its preparation method, and its application; however, these descriptions should not be construed as limiting the scope of protection of the present invention.
[0036] Example 1 Preparation method of the composition Hydroxyphenylpropionamide benzoic acid (A) and asiaticoside (C) were dissolved in anhydrous ethanol. Dipotassium glycyrrhizate (G) and tetrahydromethylpyrimidine carboxylic acid (E) were dissolved in ultrapure water. The above A, C, G and E were mixed evenly in a mass ratio of 0.15:0.1:0.3:0.5 to obtain a pharmaceutical composition with a working concentration of 20 mg / mL of hydroxyphenylpropionamide benzoic acid.
[0037] Example 2 Preparation method of pharmaceutical composition The cosmetic matrix was prepared using a traditional oil-in-water (O / W) emulsification method. The specific components and formulations are shown in Table 1. Phase A (composed of purified water, glycerin, butylene glycol, panthenol, Olivem 1000 (cetearearyl oleate, sorbitan oleate), 50% EPIGEL 305 (polyacrylamide / C13-14 isoparaffin / laurate-7), and anoin (glyceryl glucoside / water / 1,2-pentanediol), 1,2-hexanediol, and p-hydroxyacetophenone) was placed in a constant temperature water bath (DK-S22, Shanghai Jinghong, China) and heated to 80-85°C with mechanical stirring (RW20, IKA, Germany) until completely dissolved. Simultaneously, Phase B (composed of caprylic / capric triglycerides, polydimethylsiloxane, bisabolol, and cetearyl alcohol) was heated to the same temperature. Oil phase B was added to aqueous phase A and emulsified for 5 minutes at 5500 rpm using a high-speed homogenizer (MARK II Model 25, Primix, Japan) at 75–78°C. After cooling to 58–60°C, phase C (remaining polyacrylamide / C13-14 isoparaffin / laurate ether-7) was added and homogenized for three minutes. Then, the mixture was further cooled to below 45°C. At this temperature, phase D (ingredient #15, denoted as CeraProCare AC 60 (a ceramide complex containing ceramide NP, ceramide EOP, cholesterol, etc.)) was added by continuous homogenization. Finally, collagen was added, and the formulation was cooled to below 35°C with gentle stirring to obtain a homogeneous excipient cream.
[0038] The preparation method of the pharmaceutical composition is the same as that of the cosmetic matrix. The difference is that three active ingredients are added to the A phase before emulsification: asiaticoside (0.15g), dipotassium glycyrrhizate (0.3g), and ectoine (0.5g); while raw material 7 (of which the mass of hydroxyphenylpropionamide benzoic acid is 0.1g) is added during the cooling stage of the D phase.
[0039] Table 1 Cosmetic Base Formulation
[0040] Olivem 1000: Purchased from Hallstar Beauty and Personal Care Solutions Company, batch number: 6000054785. It is made from olive oil, which is hydrolyzed and then distilled to obtain fatty acids. These fatty acids undergo esterification reactions with cetearyl alcohol and sorbitan, respectively, to produce cetearyl oleate and sorbitan oleate. After mixing, the products are tableted and bottled to finally produce Olivem.® 1000.
[0041] SEPIGEL 305: Purchased from SEPPIC SA, lot number: 251022013301. Reverse emulsion polymerization: First, an aqueous phase containing the monomer is prepared. Then, it is emulsified with a lipid phase, followed by polymerization.
[0042] CeraProCare AC 60: Purchased from Evonik Operations GmbH, lot number: EP26522179. This product is obtained by emulsifying the components.
[0043] Annoin: Spirulina is cultivated on a large scale using standardized raceway tanks to supply raw materials for glycerol glycoside (GG) extraction. The GG synthesis pathway within algal cells is activated using SCGP technology, leading to the continuous accumulation of naturally occurring 2aGG within the cells. Spirulina is harvested at a specific growth cycle. A non-destructive cell extraction technique is used to alter the intracellular and extracellular environment, causing the target product, GG, to be actively secreted extracellularly, forming a GG extract. Simultaneously, the cell structure is preserved, allowing for either a new round of cultivation or direct use in the production of spirulina powder. The GG extract undergoes multiple physical purification processes at a high-value product refining center, ultimately yielding a high-purity, highly bioactive, naturally occurring GG product.
[0044] Example 3 Effects of the composition on keratinocyte activity and the expression of Th2-type immune response-related factors I. Experimental Materials 1 Experimental Cells Human immortalized keratinocyte HaCat cell line.
[0045] 2. Reagents and Tests Each drug component, IL-31, TSLP, CCL17, IL-33 primers, DMEM high glucose medium, fetal bovine serum, CCK8 detection kit, and RNA extraction kit.
[0046] 3. Instruments and Equipment Biosafety cabinets, cell incubators, inverted microscopes, fully automated microplate readers, qPCR analyzers, reverse transcriptase analyzers, centrifuges, water baths, -80°C freezers, -20°C freezers, 4°C freezers, 0.01% balances, 96-well plates, 6-well plates, disposable pipettes, pipettes and tips in various sizes such as 1000ul, 200ul, and 10ul, and centrifuge tubes in 50ml, 15ml, and 2ml.
[0047] II. Experimental Methods 1. HaCat cell culture Human immortalized keratinocyte HaCat cell line was cultured in a high-glucose DMEM culture medium containing 10% FBS at 37°C in a cell culture incubator. The medium was changed every 24 h. Cells were passaged at 60%–70% confluence to maintain logarithmic growth. After passage 3 and reaching stable condition, the cells were used for experiments.
[0048] To induce AD-like HaCat cells with AD characteristics, 10 ng / mL of IFN-γ and 10 ng / mL of TNF-α were added to high-glucose DMEM medium, and the cells were cultured at 37°C and 5% CO2 for 24 h. Subsequent experiments were conducted based on this.
[0049] 2. Drug preparation The drug components obtained in Example 1 were added to DMEM medium to a volume of 10 mL and vortexed to obtain the drug stock solution containing hydroxyphenylpropionamide benzoic acid (A, 20 mg / mL), asiaticoside (C, 50 mg / mL), dipotassium glycyrrhizate (G, 50 mg / mL), and tetrahydromethylpyrimidine carboxylic acid (E, 50 mg / mL). The culture media containing the drug components used in cell experiments were prepared by diluting the above drug stock solution proportionally.
[0050] 3. CCK8 assay for HaCat cell viability To investigate the effects of each drug component on the viability of immortalized human keratinocytes (HaCat cells), HaCat cells in the logarithmic growth phase were digested with trypsin for 5-8 min. After digestion was terminated by adding an equal volume of high-glucose DMEM medium, the cells were centrifuged at 1500 rpm for 2 min, the supernatant was discarded, and the cells were mixed by pipetting. The appropriate cell count was performed, and the corresponding cell numbers were added to the appropriate culture medium at a concentration of 2 × 10⁶ cells / mL. 5 The samples were seeded at a density of 100 μL / ml into 96-well plates, allowing them to adhere to the walls. A control group was included. Drug solutions A (20 mg / mL), C (50 mg / mL), G (50 mg / mL), and E (50 mg / mL) were diluted with high-glucose DMEM medium to the following concentrations: A: 2500, 2000, 1000, 750, 500, 350, 200, 100, 50, 10, 1 μg / mL; C, G, or E: 2500, 2000, 1000, 800, 600, 500, 100, 10, 1 μg / mL. Each group was divided into three replicates, with 200 μL per well. The control group was incubated with an equal volume of DMEM medium for 24 h. Discard the upper layer of culture medium from the 96-well plate, add 100 μL of serum-free DMEM solution containing 10% CCK8, and incubate at 37°C in a 5% CO2 cell culture incubator for 1 h. Measure the OD using a microplate reader. 450The cell viability is calculated using formula I.
[0051] Cell viability (%) = (Drug OD value - PBS well OD value) / (Blank control group OD value - PBS well OD value) × 100% Formula I.
[0052] 4. Detection of Th2-type immune response-related factors in HaCat cells using qPCR. HaCat cells were spaced at 1.5 × 10⁶ cells per well. 4 The cells were seeded in 6-well plates with 3 replicates per group. An AD-like HaCat cell model was established by induction as described in step 1. Subsequently, high-glucose DMEM medium containing the control group's drug composition was prepared according to the concentration results determined by cytotoxicity experiments, with a C:1:1:1 mass ratio of C, A, G, and E, resulting in a concentration of component A of 300 μg / mL. Medium containing the drug composition was also prepared with a C:1.5:3:5 mass ratio of C, A, G, and E, resulting in concentrations of A, C, G, and E of 300 μg / mL, 450 μg / mL, 900 μg / mL, and 1500 μg / mL, respectively. Medium containing the CAG drug composition, CAE drug composition, CGE drug composition, and AGE drug composition were also prepared according to the concentrations of each component in the drug composition. During the experiment, the medium containing different drug components was added to different wells of the plates and incubated for 24 h. The drug solution was then discarded, and total RNA was extracted from the cells according to the RNA extraction kit instructions, followed by reverse transcription. Based on the gene sequences of inflammation-related genes (IL-31, TSLP, CCL17, IL-33), specific primers were designed and synthesized for 40 cycles of real-time quantitative PCR. The PCR system and procedure are shown in Table 2. Each target was tested three times, and the average CT value was calculated. GAPDH was used as an internal reference gene, and the comparison CT (2... -ΔΔCT The relative gene expression level was determined by the method shown in Table 3.
[0053] Table 2 Reaction System and Setup Procedure
[0054] Table 3 Primers and sequences used for detection.
[0055] III. Experimental Results 1. Effects of drug components on keratinocyte activity The effects of different concentrations of the drug component on HaCat cell growth were investigated, and the results are shown in Table 4. Figure 1 As shown.
[0056] Table 4. Effects of each drug component on HaCat cell viability
[0057] It can be clearly seen that asiaticoside at concentrations below 800 μg / mL, hydroxyphenylpropionamide benzoic acid at concentrations below 350 μg / mL, dipotassium glycyrrhizate at concentrations below 2500 μg / mL, and ectoine have minimal impact on cell viability, suggesting weak cytotoxicity. These concentrations can be selected for subsequent experiments.
[0058] 2. Effects of the drug composition on the expression of Th2-type immune response-related factors The effects of different drug combinations on the expression of Th2-type immune response-related factors produced by AD-like HaCat cells were investigated. The results are shown in Table 5. Figure 2 As shown.
[0059] Table 5. Effects of the drug composition on the expression of Th2-type immune response-related factors.
[0060] The relative gene expression of IL-33 in the model group was approximately 2.1-fold higher than that in the control group. AGE and CAG significantly reduced IL-33 expression in all three drug administration groups and the proportional mixture group, with relative expression levels of 1.13±0.25 and 1.32±0.31, respectively. However, the CAGE group showed a more significant inhibitory effect on IL-33 expression, with a relative expression level of 0.79±0.20. The relative gene expression of CCL17 in the model group was approximately 4.8-fold higher than that in the control group. None of the three drug administration groups or the proportional mixture group reduced CCL17 expression, while the CAGE group significantly inhibited the relative gene expression level of CCL17, with a relative expression level of 1.41±0.73. The relative gene expression of IL-31 in the model group was approximately 13.1-fold higher than that in the control group. All drug administration groups significantly inhibited the relative gene expression level of IL-31. The relative gene expression of TSLP in the model group was approximately 2.1-fold higher than that in the control group. Both CAG and CAGE significantly reduced TSLP mRNA expression, with relative expression levels of 0.92 ± 0.35. Although the three-component administration groups and the equal-ratio administration groups could inhibit the mRNA expression of IL-33, CCL17, IL-31, and TSLP to some extent, the CAGE group showed an inhibitory effect on the mRNA expression of all indicators, and the effect was more pronounced.
[0061] Example 4 Effects of the drug composition on mouse-related immune cells I. Experimental Materials 1. Laboratory animals Female BALb / c mice (body weight about 20g, 4-6 weeks old) were purchased from SPF (Beijing) Biotechnology Co., Ltd. The mice were housed in the animal room of Shanghai Skin Disease Hospital, with an ambient temperature of 20-26°C, and provided with standard feed and water. Animal Quality Certificate No.: SCXK (Beijing) 2024-0001. Animal Use License No.: SYXK (Shanghai) 2025-0001. The laboratory animals used in this example were reviewed and approved by the Care and Use Committee of Shanghai Skin Disease Hospital (Ethics Approval No.: 2021-107).
[0062] 2. Test drugs and reagents Each drug component, PBS buffer, RPMI 1640 medium, fetal bovine serum, Naive CD4 + T cell isolation kit, T cell activation kit, PE-labeled anti-mouse IL-4 antibody, APC-labeled anti-mouse CD4 antibody, β-mercaptoethanol, cytokines IL-2, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF), thymic stromal lymphopoietin (TSLP), Zombie AquaTM cell viability dye, APC-labeled anti-mouse CD80 antibody, PE-labeled anti-mouse CD86 antibody, FITC-labeled anti-mouse OX40L antibody, as well as PE-cy7-labeled anti-mouse CD11c antibody, anti-mouse IL12 / IL23 p40 antibody, anti-mouse IFNγ antibody, and red blood cell lysis buffer.
[0063] 3. Instruments and equipment Biosafety cabinet, constant-temperature cell incubator, inverted microscope, centrifuge, water bath, -80°C refrigerator, -20°C refrigerator, 4°C refrigerator, one-ten-thousandth analytical balance, ophthalmic surgical scissors, surgical forceps, 24-well plate, magnetic stand, disposable pipette, pipettes and pipette tips of different specifications such as 1000μL, 200μL, 10μL, 50mL, 15mL and 2mL centrifuge tubes, 5mL, 1mL syringes, 200-mesh sieve.
[0064] II. Experimental methods 1. Extraction and culture of mouse bone marrow-derived dendritic cells (BMDCs) Balb / c mice were euthanized and sterilized by immersion in 75% ethanol for approximately 5 minutes. The femurs and tibias were then isolated. All surrounding muscle tissue was removed using scissors and forceps, and both ends of the bones were severed. The bone tissue was immersed in 75% ethanol for 1 minute, washed with sterile PBS, and transferred to new wells containing sterile PBS. The bone marrow cavity was flushed with 1640 complete culture medium using a syringe until it turned white. The flushed bone marrow fluid was collected, filtered through a 200-mesh sterile filter, and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded, and 3 mL of erythrocyte lysis buffer was added to the pellet. After lysis for 5 minutes, the pellet was centrifuged again at 1200 rpm for 5 minutes, followed by washing the cell pellet with sterile PBS. Finally, the isolated BMDCs were seeded into six-well plates and cultured in 1640 complete culture medium containing 20 ng / mL IL-4, 20 ng / mL GM-CSF, and 10% fetal bovine serum. After culturing for 2 days, gently shake the plate and replace half the culture medium; continue culturing for another 2 days, then replace half the culture medium again. Add BMDC at a ratio of 1×10⁻⁶. 5 Cells were seeded at a density of cells / well in 24-well plates and treated with 50 ng / mL TSLP or different concentrations of drug combinations (C, A, G, and E in a mass ratio of 1:1.5:3:5). Control groups (containing factor medium), model groups (TSLP), and high, medium, and low concentration drug combination groups (different concentrations of drug combination + TSLP) were set up and incubated for 24 hours. Cells were collected on day 5 of culture and stained using the Zombie Aqua™ live / dead staining kit, APC-labeled anti-CD80 antibody, PE-labeled anti-CD86 antibody, FITC-labeled anti-OX40L antibody, and PE-cy7-labeled anti-CD11c antibody. Flow cytometry was used to detect the maturity of BMDCs.
[0065] 2. Mouse spleen-derived Naive CD4 + T cell extraction and culture BALB / c mice were euthanized and sterilized in 75% ethanol for approximately 5 minutes. The spleens were then removed and placed in PBS buffer containing 0.1% penicillin and antibiotics, with PBS containing 2% serum as the culture medium. The spleens were ground, filtered through a 200-mesh sieve, centrifuged at 300g for 10 minutes, and resuspended in 2 mL of culture medium. Na... Sorting was performed using a CD4 sorting kit and magnetic beads. To induce Th2 polarization, 1640 medium containing 25 U / ml IL-2, 40 ng / ml IL-4, 10 μg / ml anti-mouse IL-12 / IL-23 p40 antibody, 10 μg / ml anti-mouse IFN-γ antibody, 50 mM β-mercaptoethanol, and 10% fetal bovine serum was used. Subsequently, CD3 and CD28 antibodies were added at a volume ratio of 1:100 to activate and culture Na+. ve CD4 + T cells. The cells were spaced at a rate of 1 × 10⁻⁶. 6 One culture per well was seeded into a 24-well plate and cultured. After 3 days of culture, the culture was gently shaken and passaged into three wells to form a control group (Naive CD4). + T), model group (containing factor culture medium), high, medium, and low concentration drug composition groups (different concentration drug compositions + factor culture medium), so that Na ve CD4 + T cells were cultured for 4 days in culture medium containing cytokines or in solutions of drug compositions at different concentrations. Cells were collected on day 7 and stained using the Zombie Aqua™ fixable live cell staining kit, APC anti-CD4 antibody, and PE anti-IL-4 antibody. Th2 cell polarization was detected by flow cytometry.
[0066] 3. Preparation of drug composition solution The drug composition was diluted to three concentrations (high:A:C:G:E=300:450:900:1500 μg / mL), medium:A:C:G:E=150:225:450:750 μg / mL, and low:A:C:G:E=75:112.5:225:375 μg / mL) using the complete culture medium containing cytokines described in steps 1 and 2, respectively.
[0067] III. Experimental Results 1. The inhibitory effect of the drug composition on the maturation of TSLP-induced bone marrow-derived dendritic cells. The effects of different concentrations of the drug combination on the maturation of TSLP-induced bone marrow-derived dendritic cells and Th2-type DC cells (highly expressing OX40L) were investigated. The results are shown in Table 6. Figure 3 As shown.
[0068] Table 6. Effects of different concentrations of drug compositions on the maturation of TSLP-induced bone marrow-derived dendritic cells and Th2-type DC cells.
[0069] TSLP stimulation significantly upregulated the expression of CD80, CD86, and OX40L in BMDCs, indicating successful induction of a mature DC phenotype with Th2-promoting polarization capabilities. Treatment with the drug composition resulted in a concentration-dependent decrease in CD80 and CD86 expression; simultaneously, low-dose drug composition downregulated OX40L expression, suggesting that the drug composition could attenuate TSLP-induced DC maturation and inhibit OX40L-mediated Th2-promoting polarization signaling within a certain concentration range.
[0070] 4. The effect of the drug composition on initial CD4 + Inhibition of T cell polarization into Th2 cells The effects of different concentrations of drug compositions on Na were investigated. ve CD4 + The effect of Th2 polarization on T cells, the results are shown in Table 7 and Figure 4 As shown.
[0071] Table 7. Effects of different concentrations of drug compositions on Na+ ve CD4 + The influence of Th2 polarization of T cells
[0072] Data shows that Na extracted and sorted from the spleens of Balb / c mice contains... With increasing concentration of the drug composition, CD4 T cells were induced to adopt a Th2 phenotype. + T cells (CD4) + IL-4 + The proportion of Th2 cells decreased significantly. Although the proportion of Th2 cells in the solvent group decreased (49.3%) compared to the Th2 polarization model group, suggesting that the solvent system itself has a certain inhibitory effect on T cell polarization, at high concentrations, approximately 0.6% of the Th2 phenotype was induced, a level far lower than that in the solvent group. This result confirms that the drug composition has a significant effect on Na+ polarization. ve CD4 + Inhibits the Th2 polarization of T cells.
[0073] Example 5 Anti-inflammatory and anti-allergic effects of the drug composition on a calcipotriol-induced mouse ear swelling and inflammation model I. Experimental Materials 1. Laboratory animals Female BALb / c mice (body weight about 20 g, 4-6 weeks old) were purchased from SPF (Beijing) Biotechnology Co., Ltd. The mice were housed in the animal room of Shanghai Dermatology Hospital at an ambient temperature of 20-26°C, with standard feed and water provided. Animal quality certificate number: SCXK (Jing) 2024-0001. Animal use license number: SYXK (Hu) 2025-0001. The experimental animals used in this example were reviewed and approved by the Care and Use Committee of Shanghai Dermatology Hospital (Ethics Approval No.: 2021-107).
[0074] 2. Test Drugs and Reagents The pharmaceutical composition CAGE prepared according to the method in Example 2, the base corresponding to the index in Example 2, tacrolimus, and calcipotriol.
[0075] 3. Instruments and Equipment Vernier caliper, transepidermal water loss detector.
[0076] II. Experimental Methods 1. Ear Thickness and Transepidermal Water Loss Detection 25 BALB / c mice were randomly divided into five groups (n = 5 in each group): control group, model group, base control group, positive control group, and pharmaceutical composition group. Except for the blank control group, 20 μL of ethanol solution containing 2 nmol calcipotriol was topically applied to both the inner and outer sides of the ears of mice in all other groups for 10 consecutive days, while the mice in the control group were treated with an equal volume of ethanol solution. Drug administration treatment was started from the first day of calcipotriol application, twice a day for 10 consecutive days: the base control group (Base) was administered the cream base without active ingredients, the positive control group was administered tacrolimus cream, the coating dose of the pharmaceutical composition was 25 mg / ear, the coating dose of tacrolimus cream was 25 mg / ear, and the coating amount of the cream base was equal to the coating base amount of the pharmaceutical composition group. All treatments were applied topically to both sides of the ears. On days 0, 4, 7 and 10, a vernier caliper was used to measure and record the skin thickness at a consistent position, and the severity of skin inflammation was evaluated according to the Eczema Area and Modified Severity Index (EASI) scoring standard (sum of grades of three clinical features), wherein the EASI index includes three clinical signs: erythema, edema / exudation and desquamation. Each symptom was graded from 0 to 4 according to its severity: 0 (absent), 1 (mild), 2 (moderate), 3 (moderately severe), 4 (severe). Photographs of the appearance of the mouse ears were taken at the treatment endpoint, and transepidermal water loss (TEWL) was measured at the start and end points of the treatment, respectively.
[0077] 2. Histopathological Detection Experimental Procedures for Tissue Paraffin-Embedded Sectioning ① Tissue sampling: The mouse ear tissue was fixed in 4% paraformaldehyde for more than 24 h, and the target tissue was trimmed. Note that the operation must be carried out in a fume hood. After trimming, the tissue was placed in a dehydration cassette and labeled.
[0078] ② Dehydration: Dehydrate the dehydration box according to the following dehydration sequence and concentration.
[0079] 75% alcohol 4h - 85% alcohol 2h - 90% alcohol 2h - 95% alcohol 1h - Anhydrous ethanol I 30min - Anhydrous ethanol II 30min - Alcohol benzene 5-10min - Xylene I 5-10min - Xylene II 5-10min - Wax I 1h - Wax II 1h - Wax III 1h.
[0080] ③ Embedding and Sectioning: Melt the wax and place it in an embedding frame. After the wax solidifies, place the tissue into the embedding frame for embedding and label it. After the wax solidifies, remove the wax block from the embedding frame and trim it. After trimming, section the wax block on a paraffin microtome to a thickness of 4μm. Let the sections float on 40℃ warm water in a slide to flatten the tissue, then pick them up with a glass slide and place them in a 60℃ oven to dry the water and melt the wax. After that, remove them and store them at room temperature for later use.
[0081] 3. H&E staining experimental procedures ① Dewaxing of paraffin sections: Place the sections in the following order from top to bottom: Xylene I for 20 min - Xylene II for 20 min - Anhydrous ethanol I for 10 min - Anhydrous ethanol II for 10 min - 95% ethanol for 5 min - 90% ethanol for 5 min - 80% ethanol for 5 min - 70% ethanol for 5 min - Wash with distilled water.
[0082] ②Hematoxylin staining of cell nuclei: Stain the sections with Harris hematoxylin for 3-8 minutes, then wash with tap water. Next, differentiate with 1% hydrochloric acid alcohol for a few seconds, rinse again with tap water, and finally blue with 0.6% ammonia water and rinse with running water.
[0083] ③ Eosin staining of cytoplasm: Immerse the section in eosin staining solution for 1-3 minutes.
[0084] ④ Dehydration and mounting: Place the sections in 95% alcohol I for 5 min, 95% alcohol II for 5 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, xylene I for 5 min, and xylene II for 5 min to dehydrate and clear them. Remove the sections from the xylene and let them dry slightly before mounting them with neutral resin.
[0085] ⑤ Image acquisition: Observe and describe under an optical microscope, take pictures of the main described areas, and count inflammatory cells.
[0086] 4. Immunofluorescence and immunohistochemical staining procedures After fixation and blocking, sections were incubated overnight at 4°C with primary antibody CD4 (1:500). Then, they were incubated at 37°C for 1 hour with HRP-labeled anti-rabbit IgG secondary antibody (1:200). After DAB staining and hematoxylin counterstaining, CD4-positive cells were counted in three random microscopic fields (20×).
[0087] Mouse ear lesion tissue sections were obtained, fixed, and blocked. F4 / 80-AF488 and CD206-AF594 fluorescently labeled antibodies were added, and the sections were incubated in the dark to label macrophage and M2 macrophage-related markers, respectively. After incubation, the sections were washed with PBS, and DAPI was added for nuclear counterstaining. The sections were then mounted and observed under a fluorescence microscope, and images were acquired. F4 / 80... + CD206 + Double-positive cells were analyzed as M2 type macrophages.
[0088] III. Experimental Results 1. Effect of the drug composition on calcipotriol-induced thickening of the mouse ear. A mouse model of atopic dermatitis of the auricle was established using calcipotriol (Model group). A control group (Control group), a drug-containing matrix group (Base group), and a positive control group (Tacrolimus) were also included. All three groups received intervention for 10 days (twice daily). Ear thickness measured with calipers was used as an indicator of symptom relief. Specific results are shown in Table 8 and [Table data missing]. Figure 5 .
[0089] Table 8. Effects of the drug composition on calcipotriol-induced ear thickening in mice.
[0090] Compared to the control group, the model group and the matrix group showed significant erythema, desquamation, and even crusting. In contrast, the tacrolimus group and the drug combination group showed reduced symptoms, significantly decreased erythema and desquamation, and no crusting. H&E staining results also showed that calcipotriol-induced lesions exhibited significant pathological changes, including epidermal hyperplasia, acanthosis, hyperkeratosis with parakeratosis, significant intercellular edema (sponge formation), and elongated rete ridges. These pathological changes were improved to varying degrees after the use of tacrolimus and the drug combination.
[0091] The drug composition significantly treated the ear thickening symptoms induced by calcipotriol in mice with atopic dermatitis, with the ear thickness being only 67.7% of that in the model group. The matrix group, due to the presence of other non-drug components in the cream that maintain barrier function and reduce inflammation (such as panthenol and bisabolol), also showed some relief compared to the model group, with the ear thickness being 81.6% of that in the model group.
[0092] 2. Effects of the drug composition on ear edema, erythema, and desquamation in mice. The scores of ear edema, erythema, and desquamation in mice were examined throughout the entire treatment period for each administration group, including the drug composition. The results are shown in Table 9. Figure 6 As shown.
[0093] Table 9. Effects of the drug composition on ear edema, erythema, and desquamation in mice.
[0094] Compared with the control group, the total erythema, edema, and desquamation scores in the model group increased significantly by approximately 3.9, 3.7, and 3.5 points, respectively. Treatment with tacrolimus and the drug combination significantly reduced these scores. Compared with the model group, the scores in the tacrolimus-positive control group decreased by approximately 2.2, 1.5, and 1.2 points, respectively, while the drug combination showed comparable remission levels to the tacrolimus group, reducing scores by 1.9, 1.6, and 1.1 points, respectively, demonstrating its remission effect on atopic dermatitis.
[0095] 3. Effects of the drug composition on transcutaneous water loss from mouse auricle The transdermal water loss in the mouse ears was examined throughout the entire treatment period for each drug administration group, including the drug composition, compared to before the start of the experiment. Results are shown in Table 10 and... Figure 7 As shown.
[0096] Table 10. Transdermal water loss in mouse ears compared to before the experiment.
[0097] 4. The inhibitory effect of the drug composition on ear inflammation. The fluorescence intensity of F4 / 80 and CD206 double positivity represents the infiltration of M2-type polarized (inflammatory phenotype) macrophages, which is used as an indicator of inflammation. See below for specific results. Figure 8 .
[0098] Immunofluorescence results also showed that after administration of tacrolimus and the drug combination, the infiltration of M2 macrophages in the ear tissue was reduced compared with the matrix group and the model group, further demonstrating its anti-inflammatory effect.
[0099] 5. The drug composition's effect on CD4 + Inhibition of T cell infiltration into skin tissue The stained (positive) areas in the slide represent CD4. +The infiltration of T cells, namely the activation of immune cells, was used as an evaluation indicator for inflammation, and the specific results are shown in Table 11 and Figure 9 .
[0100] Table 11 CD4 + Positive cell count of T cells infiltrating in skin tissue (cells / 20× field of view)
[0101] Immunohistochemical results showed that after calcipotriol induction, the number of CD4+ T cells in the model group increased significantly (p<0.0001), and the CD4 in the affected skin of the drug-free matrix group + Cell infiltration was still similar to that in the model group. In contrast, topical application of the pharmaceutical composition effectively reduced its activation (p<0.0001), with a degree of relief comparable to that of the positive control group.
[0102] Example 6 Repair effect of the pharmaceutical composition on the skin barrier I. Experimental materials 1. Experimental animals Female BALb / c mice (body weight about 20g, 4-6 weeks old) were purchased from SPF (Beijing) Biotechnology Co., Ltd. The mice were housed in the animal room of Shanghai Skin Disease Hospital, with an ambient temperature of 20-26℃, and provided with standard feed and water. Animal quality certificate number: SCXK (Beijing) 2024-0001. Animal use license number: SYXK (Shanghai) 2025-0001. The experimental animals used in this example were reviewed and approved by the Nursing and Use Committee of Shanghai Skin Disease Hospital (Ethics approval number: 2021-107).
[0103] 2. Test drugs and reagents The pharmaceutical composition CAGE and matrix prepared according to the method in Example 3, tacrolimus, calcipotriol, PMSF, RIPA lysis buffer, BCA kit, 10% SDS-PAGE, transfer buffer, rapid blocking buffer, TBST, primary antibodies (including PPARγ, Occludin, Claudin1, GAPDH), and HRP-labeled secondary antibody.
[0104] 3. Instruments and equipment Transblot instrument, biosafety cabinet, constant temperature cell incubator, inverted microscope, qPCR detector, reverse transcription instrument, centrifuge, water bath, -80℃ refrigerator, -20℃ refrigerator, 4℃ refrigerator, one ten-thousandth balance, 96-well plate, 6-well plate, disposable pipettes, pipettes and tips of different specifications such as 1000ul, 200ul, 10ul, 50ml, 15ml and 2ml centrifuge tubes.
[0105] II. Experimental methods 1. Detection of mRNA expression levels of keratinocyte barrier-related factors in AD-like skin by drug composition. HaCat cells were spaced at 1.5 × 10⁶ cells per well. 4 The cells were seeded in 6-well plates, with 3 replicates per group. An AD-like HaCat cell model was established by induction according to step 1 of Example 4. High-glucose DMEM medium containing the drug composition (A:C:G:E = 300:450:900:1500 μg / mL) was then added to the wells and incubated for 24 h. The drug solution was then discarded, and total RNA was extracted from the cells according to the RNA extraction kit instructions, followed by reverse transcription. Specific primers were designed and synthesized based on the gene sequences of barrier-related genes (TJP3, FLG). Real-time quantitative PCR was performed for 40 cycles. The procedure was the same as in Table 2 of step 4. Each target was tested three times repeatedly, and the average CT value was calculated. GAPDH was used as an internal reference gene, and the CT (2... -ΔΔCT The relative gene expression level was determined using a method shown in Table 12.
[0106] Table 12 Primers and sequences used for detection
[0107] 2. Detection of the restoration of calcipotriol-induced expression levels of ear barrier-related proteins in mice by the drug composition. Approximately 30 mg of ear tissue was weighed and protein was extracted using 300 μL of RIPA lysis buffer containing 3 μL PMSF and 6 μL phosphatase inhibitor. Protein concentration was determined using the BCA method, and total protein was separated using 10% SDS-PAGE. The membrane was then transferred and blocked with rapid blocking buffer for 8 minutes. After blocking, the membrane was washed three times with TBST and incubated overnight at 4°C with primary antibodies (PPARγ (1:5000 dilution), Occludin (1:5000 dilution), Claudin1 (1:1000 dilution), and GAPDH (1:25000 dilution). The membrane was then incubated with HRP-labeled secondary antibody (1:1000 dilution) for 1 hour at room temperature to detect antibody binding. Protein bands were quantified and analyzed using the ImageJ system. Finally, data were expressed as band intensities normalized to GAPDH or their respective total protein values.
[0108] III. Experimental Results 1. Detection of mRNA expression levels of keratinocyte barrier-related factors in AD-like skin by drug composition. The effects of different drug combinations on the expression of skin barrier-related factors produced by AD-like HaCat cells were investigated. The results are shown in Table 13 and... Figure 10 As shown.
[0109] The results show that the application of the pharmaceutical composition to AD-like HaCat cells upregulates the barrier-related gene FLG( p<0.0001) and TJP3( p<0.01) expression.
[0110] Table 13 The pharmaceutical composition restores the mRNA expression levels of barrier-related factors in AD-like skin keratinocytes
[0111] 2. Detection of the pharmaceutical composition restoring the expression levels of barrier-related proteins in mouse ears induced by calcipotriol The effect of the pharmaceutical composition on the expression of skin barrier-related proteins in the AD-like mouse ear model was investigated, and the results are shown in Table 14 and Figure 11 as shown.
[0112] WB results showed that the expression of tight junction proteins Claudin-1 and Occludin in the model group decreased significantly, suggesting that the epidermal barrier integrity in AD-like skin lesions was impaired. After treatment with the pharmaceutical composition, the expression of Claudin-1 and Occludin was significantly restored, indicating that the pharmaceutical composition can improve the tight junction barrier. Notably, the expression of PPARγ in the model group was significantly increased, while the expression of PPARγ after CAGE treatment was restored to a level close to normal, suggesting that the increase of PPARγ in the AD model may be a compensatory response after barrier injury, and the pharmaceutical composition can correct this abnormal compensatory state and promote barrier repair.
[0113] Table 14 Effect of the pharmaceutical composition on the expression of skin barrier-related proteins in the AD-like mouse ear model
[0114] Example 7 Safety evaluation of the pharmaceutical composition I. Experimental materials 1. Experimental animals Female BALb / c mice (body weight about 20g, 4-6 weeks old) were purchased from SPF (Beijing) Biotechnology Co., Ltd. The mice were kept in the animal room of Shanghai Skin Disease Hospital, with an ambient temperature of 20-26°C, and provided with standard feed and water. Animal quality certificate number: SCXK (Beijing) 2024-0001. Animal use license number: SYXK (Shanghai) 2025-0001. The experimental animals used in this example were reviewed and approved by the Institutional Animal Care and Use Committee of Shanghai Skin Disease Hospital (Ethics approval number: 2021-107).
[0115] 2. Test drugs and reagents The pharmaceutical composition CAGE and matrix BASE, tacrolimus, calcipotriol, creatinine (CREA), urea (BUN), uric acid (UA), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) assay kit prepared according to the method in Example 3.
[0116] II. Instruments and Equipment Fully automated blood cell analyzer, fully automated biochemical analyzer, biosafety cabinet, constant temperature incubator, fully automated enzyme-linked immunosorbent assay (ELISA) reader, centrifuge, water bath, -80°C freezer, -20°C freezer, 4°C freezer, 0.001g balance, tissue grinder, vortex mixer, anticoagulant tubes, pipettes and pipette tips of different specifications such as 1000ul, 200ul, and 10ul, and centrifuge tubes of 50ml, 15ml, and 2ml.
[0117] III. Experimental Methods Six healthy female Balb / c mice were randomly divided into a control group and a drug combination group, with n=3 animals in each group. Mouse weight was recorded every 3 days. Mice were euthanized by CO2 asphyxiation on day 10 after the first administration. Whole blood was collected for various biochemical indicators and routine blood tests.
[0118] 1. Complete blood count (CBC) Whole blood is collected using anticoagulant tubes, and the corresponding parameters are set on the fully automated blood cell analyzer for automatic sample loading and analysis.
[0119] 2. Biochemical analysis Whole blood samples were incubated at room temperature for 2 hours or overnight at 4°C, then centrifuged at 3000 rpm for 15 minutes at 4°C. The supernatant serum was collected and then tested according to the instructions of each kit.
[0120] IV. Experimental Results 1. Blood routine tests of mice using the drug composition The results in Table 15 show that all major blood routine indicators of mice treated with the drug composition fell within the safe range, demonstrating its good biocompatibility.
[0121] Table 15 Results of routine blood tests in mice
[0122] 2. Detection of biochemical indicators in mice using the drug composition. The serum of mice in the drug combination group and the control group were tested for major biochemical indicators, including creatinine (CREA), urea (BUN), uric acid (UA), alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
[0123] The results are as follows Figure 12As shown in the figure. The results showed that the major biochemical indicators of mice treated with the drug composition did not change significantly compared with the control group, further demonstrating its biosafety. The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A composition, characterized in that, Including hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate and tetrahydromethylpyrimidine carboxylic acid; The mass ratio of the hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid is 0.8~1.0:1.3~1.7:2.8~3.2:4.8~5.
2.
2. The composition according to claim 1, characterized in that, The mass ratio of the hydroxyphenylpropionamide benzoic acid, hydroxyasiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid is 1:1.5:3:
5.
3. The composition according to claim 1, characterized in that, The composition also includes skin barrier repair agents and / or anti-inflammatory agents; When the composition includes a skin barrier repair agent, the skin barrier repair agent includes one or more of ceramide NP, ceramide EOP, and cholesterol; The mass ratio of hydroxyphenylpropionamide benzoic acid, ceramide NP, ceramide EOP and cholesterol is 0.8~1.0:0.06~0.068:0.028~0.032:0.013~0.017; When the composition includes a skin barrier repair agent, the anti-inflammatory agent is bisabolol; The mass ratio of hydroxyphenylpropionamide benzoic acid to bisabolol is 0.8~1.0:1.8~2.
2.
4. The use of the composition according to any one of claims 1 to 3 in the preparation of a pharmaceutical for the prevention and / or treatment of skin inflammation or in the preparation of a cosmetic for the relief of skin inflammation.
5. The application according to claim 4, characterized in that, The skin inflammations mentioned include atopic dermatitis.
6. The application according to claim 4, characterized in that, The atopic dermatitis includes at least one of the following symptoms: skin allergy, skin inflammation, and damage to the skin barrier.
7. The application according to claim 4, characterized in that, The dosage form of the medicine includes at least one of the following external dosage forms: ointment, cream, and spray.
8. The application according to claim 4, characterized in that, The types of cosmetics include at least one of the following: lotion, cream, and lotion.
9. The application according to any one of claims 4 to 8, characterized in that, In the aforementioned pharmaceutical or cosmetic product, the concentration of dipotassium glycyrrhizate is 0.28-0.32%.
10. A product for relieving atopic dermatitis, characterized in that, Includes the composition of claim 1 or 2 and pharmaceutically or cosmetically acceptable excipients.
